Ten-eleven translocation-2 gene mutations:A potential new molecular marker in malignant gliomas (review)

Abstract

Alterations of the Ten-Eleven Translocation-2 (TET2) gene in myeloid malignancies and isocitrate dehydrogenase (IDH) gene mutations in gliomas and myeloid malignancies have recently been identified using molecular, comparative genomic hybridization and single nucleotide polymorphism array techniques. The mutations of the TET2 gene have been shown to be mutually exclusive with IDH1/2 mutations in acute myeloid leukemia (AML) and evidence has been found to provide a biochemical basis for the mutual exclusivity of IDH1/2 and TET2 gene mutations. Based on mounting evidence, we aimed to investigate whether TET2 mutations may be identified as novel mutations in malignant gliomas without IDH1/2 mutations, and indicate their possible significance in gliomas. last 5 years from an average of 10 to 14 months after diagnosis due to improvements in the standard of care (1). A comprehensive understanding of the genetic basis and pathology of gliomas has provided new information regarding biologically based tumor classification and has identified molecular prognostic biomarkers to improve the management of patients with gliomas. Over the past decades the application of sequencing, comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) array techniques have revealed the molecular genetic background of neoplasms through the identification of novel oncogenes and tumor suppressor genes.